社区
首页
集团介绍
社区
资讯
行情
学堂
TigerGPT
登录
注册
JonLucky
IP属地：未知
+关注
帖子 · 344
帖子 · 344
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
JonLucky
JonLucky
·
2021-02-11
It's inevitable
非常抱歉，此主贴已删除
看
1,619
回复
5
点赞
9
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-31
Indeed, it appears this vehicle will have to gingerly navigate the potholes ahead to emerge on the other side successfully.
The Ride Could Get Bumpy For Lucid Motors Stock
The fate of LCID stock in 2022 hinges on whether investor sentiment holds for EVs
The Ride Could Get Bumpy For Lucid Motors Stock
看
1,452
回复
评论
点赞
2
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-30
It's a paradox, but Simba will solve that in the end.
非常抱歉，此主贴已删除
看
1,357
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-30
Bullish or just bullshit. Time will tell.
Foundry for Crypto Is a Game Changer for Palantir Stock
Palantir(NYSE:PLTR) stock is a thoroughbred growth stock. It has an asset-light business model, soli
Foundry for Crypto Is a Game Changer for Palantir Stock
看
1,903
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-29
It's either an Albatross or a Crow
Apple’s March to $3 Trillion Carries Virus-Risk Warning for S&P
(Bloomberg) -- Apple Inc., whose shares serve as a real-time proxy for risk sentiment toward the pan
Apple’s March to $3 Trillion Carries Virus-Risk Warning for S&P
看
1,613
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-29
CurALeaf makes a deal to Cure-a-leaf
Cannabis Leader Curaleaf Makes a Major Expansion Play
The largest cannabis company in the country, Curaleaf(CURLF), plans to acquire Bloom Dispensaries in
Cannabis Leader Curaleaf Makes a Major Expansion Play
看
2,478
回复
1
点赞
1
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-27
The sting from a thousand ants is no less painful, nor less deadlier, than a sting from a big bad bee.
非常抱歉，此主贴已删除
看
1,669
回复
1
点赞
1
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-26
Not all matches are made in heaven
A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State
In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, t
A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State
看
1,305
回复
1
点赞
1
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-25
Why not just have them both
非常抱歉，此主贴已删除
看
2,026
回复
3
点赞
4
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-25
Mostly highly unlikely, but highly unlikely tiny when they occur.
非常抱歉，此主贴已删除
看
2,252
回复
2
点赞
6
编组 21备份 2
分享
举报
JonLucky
JonLucky
·
2021-12-25
It's a matter of time
@ngjr90：
$STI ETF(ES3.SI)$Will it breakeven?
$STI ETF(ES3.SI)$Will it breakeven?
看
1,778
回复
1
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3573703375513385","uuid":"3573703375513385","gmtCreate":1610611080049,"gmtModify":1611889862568,"name":"JonLucky","pinyin":"jonlucky","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":105,"headSize":648,"tweetSize":344,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"93.34%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.38%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":388338218,"gmtCreate":1613019801734,"gmtModify":1703768446608,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"It's inevitable ","listText":"It's inevitable ","text":"It's inevitable","images":[],"top":2,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/388338218","repostId":"2110416000","repostType":4,"isVote":1,"tweetType":1,"viewCount":1619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":692689284,"gmtCreate":1640940435257,"gmtModify":1640940436360,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"Indeed, it appears this vehicle will have to gingerly navigate the potholes ahead to emerge on the other side successfully.","listText":"Indeed, it appears this vehicle will have to gingerly navigate the potholes ahead to emerge on the other side successfully.","text":"Indeed, it appears this vehicle will have to gingerly navigate the potholes ahead to emerge on the other side successfully.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692689284","repostId":"1161129852","repostType":4,"repost":{"id":"1161129852","kind":"news","pubTimestamp":1640936405,"share":"https://www.laohu8.com/m/news/1161129852?lang=&edition=full","pubTime":"2021-12-31 15:40","market":"us","language":"en","title":"The Ride Could Get Bumpy For Lucid Motors Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1161129852","media":"InvestorPlace","summary":"The fate of LCID stock in 2022 hinges on whether investor sentiment holds for EVs","content":"<html><head></head><body><p>It’s an understatement to say <b>Lucid Group</b> (NASDAQ:<b><u>LCID</u></b>) and LCID stock had a very good 2021. But will this be the case for 2022? It depends on two things happening.</p><p>First, the EV maker will need to continue making progress at the same pace it’s been doing so lately. Second, and more importantly, its performance in 2022 hinges heavily on investor sentiment for vehicle electrification plays.</p><p>The first factor appears likely to pan out, even if it’s unclear whether Lucid can commence mass production without facing too many hiccups and hurdles. However, the jury’s still out on the second factor.</p><p>Based on how EV stocks are stabilizing, it may seem a bit alarmist to believe more deflation of the EV bubble is set to happen. Yet if the market conditions that created this bubble in the first continue to change, another round of big declines may lie ahead for Lucid, along with the higher prominent electric vehicle names like <b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) and <b>Rivian</b>(NASDAQ:<b><u>RIVN</u></b>).</p><p>If you’re bullish on the EV megatrend, you may believe LCID stock is a winner that will keep on winning. But it’s important to keep in mind how changing sentiment could affect its performance.</p><p><b>The Latest With LCID Stock</b></p><p>Settling down after its late November/early December slide, Lucid is finishing up the year quietly. Two more positive developments ($1.75 billion convertible debt offering,inclusion in the <b>NASDAQ-100</b> index) helped to counter more negative news, such as its disclosure of a Securities and Exchange Commission subpoena about the special purpose acquisition company (SPAC) deal that took it public earlier this year.</p><p>With this, plus the market calming down with its omicron/Fed worries, LCID stock has found support. As of this writing, it’s trading between $35 and $40 per share. But while the stock was a big winner in 2021 (up 280%), this may not be the case in 2022.</p><p>Again, concerns are not so much due to the risk that it drops the ball in the next 12 months. Based on how successful its execution has been this year, it’s hard to doubt that Lucid will meet its production goals for the next two years (20,000 vehicles in 2022, 50,000 vehicles in 2023).</p><p>Yet if in the months ahead, bullishness for EV plays continues to cool down? Meeting and/or beating near-term expectations may not be enough for it to hold onto its rich valuation.</p><p><b>Rising Rates Could Still Keep Lucid in Reverse</b></p><p>The market’s appetite for growth stocks played a big role in sending LCID stock to the moon this year. However, based on how sentiment is shifting, this may not continue in the months ahead.</p><p>That is, market environment is more likely to become more unfavorable to growth stocks. As the Federal Reserve continues to take on a more hawkish tone, mentioning faster tapering and rate hikes for 2022, growth stocks are going to continue to lose their luster.</p><p>In turn,the pivot away from riskier assets like early-stage growth stocks will carry on. Firmly in that category, EV stocks like Lucid will likely face more downward pressure. This could far outweigh company-specific positives, such as the budding automaker successfully ramping up production, or wowing Wall Street with its delivery numbers.</p><p>To what extent could that affect LCID stock over the next 12 months? At this point, it’s hard to tell. We could see EV stocks experience an extended sell-off, much like what happened with internet stocks following the bursting of the dot-com bubble. As you may recall, even the dot-com winners in the making, like <b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>), saw massive drawdowns and took many years to get back to their respective high-water marks.</p><p><b>The Bottom Line</b></p><p>Based upon its success this year, it’s easy to be confident things will continue to work out favorably for Lucid. Yet whether that happens to LCID stock as well remains to be seen. The winds are blowing differently today than they were as recently as late November.</p><p>A return to normal for Fed monetary policy may signal the end of the epic run growth stocks have gone on since the start of the coronavirus pandemic. As the market’s view on EV stocks is in the driver’s seat, what’s the takeaway?</p><p>Before buying LCID stock just on your bullishness for the EV trend, take a read of the room. If it appears the cycling out of growth stocks will continue, it’s best to wait before buying it.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Ride Could Get Bumpy For Lucid Motors Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Ride Could Get Bumpy For Lucid Motors Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-31 15:40 GMT+8 <a href=https://investorplace.com/2021/12/lcid-stock-ride-could-get-bumpy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It’s an understatement to say Lucid Group (NASDAQ:LCID) and LCID stock had a very good 2021. But will this be the case for 2022? It depends on two things happening.First, the EV maker will need to ...</p>\n\n<a href=\"https://investorplace.com/2021/12/lcid-stock-ride-could-get-bumpy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc"},"source_url":"https://investorplace.com/2021/12/lcid-stock-ride-could-get-bumpy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161129852","content_text":"It’s an understatement to say Lucid Group (NASDAQ:LCID) and LCID stock had a very good 2021. But will this be the case for 2022? It depends on two things happening.First, the EV maker will need to continue making progress at the same pace it’s been doing so lately. Second, and more importantly, its performance in 2022 hinges heavily on investor sentiment for vehicle electrification plays.The first factor appears likely to pan out, even if it’s unclear whether Lucid can commence mass production without facing too many hiccups and hurdles. However, the jury’s still out on the second factor.Based on how EV stocks are stabilizing, it may seem a bit alarmist to believe more deflation of the EV bubble is set to happen. Yet if the market conditions that created this bubble in the first continue to change, another round of big declines may lie ahead for Lucid, along with the higher prominent electric vehicle names like Tesla(NASDAQ:TSLA) and Rivian(NASDAQ:RIVN).If you’re bullish on the EV megatrend, you may believe LCID stock is a winner that will keep on winning. But it’s important to keep in mind how changing sentiment could affect its performance.The Latest With LCID StockSettling down after its late November/early December slide, Lucid is finishing up the year quietly. Two more positive developments ($1.75 billion convertible debt offering,inclusion in the NASDAQ-100 index) helped to counter more negative news, such as its disclosure of a Securities and Exchange Commission subpoena about the special purpose acquisition company (SPAC) deal that took it public earlier this year.With this, plus the market calming down with its omicron/Fed worries, LCID stock has found support. As of this writing, it’s trading between $35 and $40 per share. But while the stock was a big winner in 2021 (up 280%), this may not be the case in 2022.Again, concerns are not so much due to the risk that it drops the ball in the next 12 months. Based on how successful its execution has been this year, it’s hard to doubt that Lucid will meet its production goals for the next two years (20,000 vehicles in 2022, 50,000 vehicles in 2023).Yet if in the months ahead, bullishness for EV plays continues to cool down? Meeting and/or beating near-term expectations may not be enough for it to hold onto its rich valuation.Rising Rates Could Still Keep Lucid in ReverseThe market’s appetite for growth stocks played a big role in sending LCID stock to the moon this year. However, based on how sentiment is shifting, this may not continue in the months ahead.That is, market environment is more likely to become more unfavorable to growth stocks. As the Federal Reserve continues to take on a more hawkish tone, mentioning faster tapering and rate hikes for 2022, growth stocks are going to continue to lose their luster.In turn,the pivot away from riskier assets like early-stage growth stocks will carry on. Firmly in that category, EV stocks like Lucid will likely face more downward pressure. This could far outweigh company-specific positives, such as the budding automaker successfully ramping up production, or wowing Wall Street with its delivery numbers.To what extent could that affect LCID stock over the next 12 months? At this point, it’s hard to tell. We could see EV stocks experience an extended sell-off, much like what happened with internet stocks following the bursting of the dot-com bubble. As you may recall, even the dot-com winners in the making, like Amazon(NASDAQ:AMZN), saw massive drawdowns and took many years to get back to their respective high-water marks.The Bottom LineBased upon its success this year, it’s easy to be confident things will continue to work out favorably for Lucid. Yet whether that happens to LCID stock as well remains to be seen. The winds are blowing differently today than they were as recently as late November.A return to normal for Fed monetary policy may signal the end of the epic run growth stocks have gone on since the start of the coronavirus pandemic. As the market’s view on EV stocks is in the driver’s seat, what’s the takeaway?Before buying LCID stock just on your bullishness for the EV trend, take a read of the room. If it appears the cycling out of growth stocks will continue, it’s best to wait before buying it.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692313110,"gmtCreate":1640846090463,"gmtModify":1640846091493,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"It's a paradox, but Simba will solve that in the end. ","listText":"It's a paradox, but Simba will solve that in the end. ","text":"It's a paradox, but Simba will solve that in the end.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692313110","repostId":"1193773446","repostType":4,"isVote":1,"tweetType":1,"viewCount":1357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692337352,"gmtCreate":1640845199307,"gmtModify":1640845602294,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"Bullish or just bullshit. Time will tell. ","listText":"Bullish or just bullshit. Time will tell. ","text":"Bullish or just bullshit. Time will tell.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692337352","repostId":"1150743331","repostType":4,"repost":{"id":"1150743331","kind":"news","pubTimestamp":1640842556,"share":"https://www.laohu8.com/m/news/1150743331?lang=&edition=full","pubTime":"2021-12-30 13:35","market":"us","language":"en","title":"Foundry for Crypto Is a Game Changer for Palantir Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1150743331","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) stock is a thoroughbred growth stock. It has an asset-light business model, soli","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) stock is a thoroughbred growth stock. It has an asset-light business model, solid government contracts, and a staggering amount of cash.</p><p>In recently reported earnings,it hit the ball out of the park once again. Both revenue and earnings figures beat analyst estimates. And guidance was also upbeat. Then why has PLTR stock lost a third of its value in a recent sell-off?</p><p>Well, here is where it gets interesting.</p><p>Investors are demanding when it comes to Palantir. They saw the potential, and they liked it. After all, that is what drove them in droves to the stock when it made its colossal debut last year. Much like every other tech IPOthese days, investors made money hand over fist.</p><p>But there are a few things peeving stockholders. First, they want the commercial business to start producing the goods. Palantir has an excellent record when it comes to government contracts. But the commercial business is not as successful. Investors want diversification in the revenue mix. Hence, it is a major factor affecting investor sentiment.</p><p>Potential regulatory activity is the other issue hanging over PLTR stock like a dark cloud. Due to the close association of Palantir and the defense establishment,certain members of Congress have taken issue with the big data company. In particular, the company’s contracts with the U.S. Immigration and Customs Enforcement (ICE) have come under fire.</p><p>However, Palantir is a solid enterprise that is consistently expanding. For example, Palantir has developed a new service that will support compliance regulations for cryptocurrencies. Cryptocurrencies are a hot commodity with an exciting future ahead. With cryptocurrencies being so popular and institutional adoption legitimizing this new industry, it is a potential game changer. The rest of its business is also growing nicely.</p><p>Palantir’s Expanding Commercial Business</p><p>Palantir offers multiple products to companies and governments for improving information gathering, operational capabilities. Its various platforms have wide applications across industries. The U.S military and other government agencies use Palantir’s investigative analysis capabilities to solve crime in America, abroad, or anywhere where users can apply its data-driven software.</p><p>The use of AI in government is widespread. With their Gotham platform, large organizations like Palantir have made it possible for them to integrate massive amounts of data into one operating system, which these powerful programs can then analyze – it allows analysts to perform due diligence on a massive amount of data at lightning speed.</p><p>Palantir’sFoundry option is a simple data pipeline that brings together back-end and front-end information so you can access it with ease. This breaks down barriers to understanding. It is especially helpful for those who need help managing or analyzing large sets on their own, whether they’re in corporate America looking at customer relationships across departments or an intelligence agency trying to make sense of unforeseen threats before they happen.</p><p>Palantir is expanding its Foundry offering in a big way. The company rolled out “Foundry for Builders,” an end-to-end analytics platform targeting startup companies. Palantir has added 10 more companies to its Foundry for Builders SaaS platform in October of this year – startups from all over are now using it as their go-to growth accelerator.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Foundry for Crypto Is a Game Changer for Palantir Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFoundry for Crypto Is a Game Changer for Palantir Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 13:35 GMT+8 <a href=https://investorplace.com/2021/12/foundry-for-crypto-is-a-game-changer-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) stock is a thoroughbred growth stock. It has an asset-light business model, solid government contracts, and a staggering amount of cash.In recently reported earnings,it hit the ...</p>\n\n<a href=\"https://investorplace.com/2021/12/foundry-for-crypto-is-a-game-changer-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/12/foundry-for-crypto-is-a-game-changer-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150743331","content_text":"Palantir(NYSE:PLTR) stock is a thoroughbred growth stock. It has an asset-light business model, solid government contracts, and a staggering amount of cash.In recently reported earnings,it hit the ball out of the park once again. Both revenue and earnings figures beat analyst estimates. And guidance was also upbeat. Then why has PLTR stock lost a third of its value in a recent sell-off?Well, here is where it gets interesting.Investors are demanding when it comes to Palantir. They saw the potential, and they liked it. After all, that is what drove them in droves to the stock when it made its colossal debut last year. Much like every other tech IPOthese days, investors made money hand over fist.But there are a few things peeving stockholders. First, they want the commercial business to start producing the goods. Palantir has an excellent record when it comes to government contracts. But the commercial business is not as successful. Investors want diversification in the revenue mix. Hence, it is a major factor affecting investor sentiment.Potential regulatory activity is the other issue hanging over PLTR stock like a dark cloud. Due to the close association of Palantir and the defense establishment,certain members of Congress have taken issue with the big data company. In particular, the company’s contracts with the U.S. Immigration and Customs Enforcement (ICE) have come under fire.However, Palantir is a solid enterprise that is consistently expanding. For example, Palantir has developed a new service that will support compliance regulations for cryptocurrencies. Cryptocurrencies are a hot commodity with an exciting future ahead. With cryptocurrencies being so popular and institutional adoption legitimizing this new industry, it is a potential game changer. The rest of its business is also growing nicely.Palantir’s Expanding Commercial BusinessPalantir offers multiple products to companies and governments for improving information gathering, operational capabilities. Its various platforms have wide applications across industries. The U.S military and other government agencies use Palantir’s investigative analysis capabilities to solve crime in America, abroad, or anywhere where users can apply its data-driven software.The use of AI in government is widespread. With their Gotham platform, large organizations like Palantir have made it possible for them to integrate massive amounts of data into one operating system, which these powerful programs can then analyze – it allows analysts to perform due diligence on a massive amount of data at lightning speed.Palantir’sFoundry option is a simple data pipeline that brings together back-end and front-end information so you can access it with ease. This breaks down barriers to understanding. It is especially helpful for those who need help managing or analyzing large sets on their own, whether they’re in corporate America looking at customer relationships across departments or an intelligence agency trying to make sense of unforeseen threats before they happen.Palantir is expanding its Foundry offering in a big way. The company rolled out “Foundry for Builders,” an end-to-end analytics platform targeting startup companies. Palantir has added 10 more companies to its Foundry for Builders SaaS platform in October of this year – startups from all over are now using it as their go-to growth accelerator.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696704396,"gmtCreate":1640761048662,"gmtModify":1640761049676,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"It's either an Albatross or a Crow","listText":"It's either an Albatross or a Crow","text":"It's either an Albatross or a Crow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696704396","repostId":"2194435036","repostType":4,"repost":{"id":"2194435036","kind":"news","pubTimestamp":1640759231,"share":"https://www.laohu8.com/m/news/2194435036?lang=&edition=full","pubTime":"2021-12-29 14:27","market":"us","language":"en","title":"Apple’s March to $3 Trillion Carries Virus-Risk Warning for S&P","url":"https://stock-news.laohu8.com/highlight/detail?id=2194435036","media":"Bloomberg","summary":"(Bloomberg) -- Apple Inc., whose shares serve as a real-time proxy for risk sentiment toward the pan","content":"<p>(Bloomberg) -- Apple Inc., whose shares serve as a real-time proxy for risk sentiment toward the pandemic, is near a $3 trillion market capitalization. If history is any guide, that milestone may signal a technical correction is ahead, for both the stock and the broader market.</p>\n<p>The ripple effect in those episodes went beyond just Apple. Huge gains in big tech stocks tend to drive the S&P 500 to record highs, with the benchmark potentially setting its 70th record close for the year today. But those market drivers can spur big selloffs too. Apple’s pullback after hitting the trillion-dollar milestone contributed to the bear market in the fall of 2018. It also helped fuel the tech wreck of September 2020, when the S&P 500 slid amid election-related volatility.</p>\n<p>For Apple to hit the $3 trillion market cap, its share price would need to reach $182.86. It was down less than 1% Tuesday, at about $179. Amid thin volume, the stock market has posted broad gains this week, so attaining the next trillion-dollar threshold is within reach.</p>\n<p>This comes in the face of Apple closing some stores in locations such as New York City, Los Angeles, Washington and London as the omicron variant spreads. Apple took a similar step in the summer of 2020, before the wide availability of vaccines. And when New York and some other cities were reopening, the virus was spreading to the South -- including to major GDP-contributing states like Texas and Florida.</p>\n<p>Given that Apple’s products are largely luxury items, such a move served as a real-time indicator of consumer demand and foot traffic in stores. Apple shares reacted to these steps, and the broader market saw it as a proxy for the spreading virus. Now investors are once again take their cue from this crucial stock.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple’s March to $3 Trillion Carries Virus-Risk Warning for S&P</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple’s March to $3 Trillion Carries Virus-Risk Warning for S&P\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 14:27 GMT+8 <a href=https://finance.yahoo.com/news/apple-march-3-trillion-carries-144448585.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Apple Inc., whose shares serve as a real-time proxy for risk sentiment toward the pandemic, is near a $3 trillion market capitalization. If history is any guide, that milestone may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apple-march-3-trillion-carries-144448585.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4501":"段永平概念","BK4534":"瑞士信贷持仓","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4559":"巴菲特持仓","BK4505":"高瓴资本持仓","BK4527":"明星科技股","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4515":"5G概念","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","AAPL":"苹果","BK4170":"电脑硬件、储存设备及电脑周边"},"source_url":"https://finance.yahoo.com/news/apple-march-3-trillion-carries-144448585.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2194435036","content_text":"(Bloomberg) -- Apple Inc., whose shares serve as a real-time proxy for risk sentiment toward the pandemic, is near a $3 trillion market capitalization. If history is any guide, that milestone may signal a technical correction is ahead, for both the stock and the broader market.\nThe ripple effect in those episodes went beyond just Apple. Huge gains in big tech stocks tend to drive the S&P 500 to record highs, with the benchmark potentially setting its 70th record close for the year today. But those market drivers can spur big selloffs too. Apple’s pullback after hitting the trillion-dollar milestone contributed to the bear market in the fall of 2018. It also helped fuel the tech wreck of September 2020, when the S&P 500 slid amid election-related volatility.\nFor Apple to hit the $3 trillion market cap, its share price would need to reach $182.86. It was down less than 1% Tuesday, at about $179. Amid thin volume, the stock market has posted broad gains this week, so attaining the next trillion-dollar threshold is within reach.\nThis comes in the face of Apple closing some stores in locations such as New York City, Los Angeles, Washington and London as the omicron variant spreads. Apple took a similar step in the summer of 2020, before the wide availability of vaccines. And when New York and some other cities were reopening, the virus was spreading to the South -- including to major GDP-contributing states like Texas and Florida.\nGiven that Apple’s products are largely luxury items, such a move served as a real-time indicator of consumer demand and foot traffic in stores. Apple shares reacted to these steps, and the broader market saw it as a proxy for the spreading virus. Now investors are once again take their cue from this crucial stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1613,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696702386,"gmtCreate":1640760631883,"gmtModify":1640760632938,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"CurALeaf makes a deal to Cure-a-leaf ","listText":"CurALeaf makes a deal to Cure-a-leaf ","text":"CurALeaf makes a deal to Cure-a-leaf","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696702386","repostId":"1187597556","repostType":4,"repost":{"id":"1187597556","kind":"news","pubTimestamp":1640759811,"share":"https://www.laohu8.com/m/news/1187597556?lang=&edition=full","pubTime":"2021-12-29 14:36","market":"us","language":"en","title":"Cannabis Leader Curaleaf Makes a Major Expansion Play","url":"https://stock-news.laohu8.com/highlight/detail?id=1187597556","media":"TheStreet","summary":"The largest cannabis company in the country, Curaleaf(CURLF), plans to acquire Bloom Dispensaries in","content":"<p>The largest cannabis company in the country, Curaleaf(<b>CURLF</b>), plans to acquire Bloom Dispensaries in its efforts to grow its Arizona market.</p>\n<p>As part of an all-cash deal valued at $211 million, the Wakefield, Mass.-based Curaleaf committed to purchasing the Arizona-based marijuana dispenser and two processing facilities Phoenix and multiple dispensaries in Tucson, Peoria, and Sedona.</p>\n<p>The deal is expected to close in January 2022 after regulator approval.</p>\n<p><b>Curaleaf Has Big Expansion Plans</b></p>\n<p>The move is part of Curaleaf's larger plan to expand its reach in different parts of the country and Arizona in particular — the Bloom acquisition will bring it up to 16 dispensaries in Arizona and 128 across the country.</p>\n<p>It chose Bloom, which is expected to generate $66 million in revenue and EBITDA margins of more than 40%, for its \"attractive financial profile.\"</p>\n<p>\"Bloom has built a strong and profitable business, and we believe the combination of our two companies will enhance our competitive position and ability to continue gaining share in the highly attractive Arizona market,\" Curaleaf CEO Joseph Bayern said in a press statement.</p>\n<p><b>How Is Curaleaf Paying for the Deal?</b></p>\n<p>Curaleaf will initially pay out $51 million in cash at closing. For the rest, it signed promissory notes of $50 million, $50 million, and $60 million due on the first, second, and third anniversary of the close.</p>\n<p>News of the acquisition has not had an upward effect on the company's value. Curaleaf is 34.33% to $8.48 year-over-year and down 2.59% since this morning.</p>\n<p>\"In addition to bolstering our strong position in this key growth market with an attractive portfolio of retail and cultivation assets, Bloom will be immediately accretive to our adjusted EBITDA margins upon close,\" says Curaleaf Executive Chairman Boris Jordan.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cannabis Leader Curaleaf Makes a Major Expansion Play</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCannabis Leader Curaleaf Makes a Major Expansion Play\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 14:36 GMT+8 <a href=https://www.thestreet.com/investing/curaleaf-buys-bloom-dispensaries-for-211-million?puc=yahoo&cm_ven=YAHOO><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The largest cannabis company in the country, Curaleaf(CURLF), plans to acquire Bloom Dispensaries in its efforts to grow its Arizona market.\nAs part of an all-cash deal valued at $211 million, the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/curaleaf-buys-bloom-dispensaries-for-211-million?puc=yahoo&cm_ven=YAHOO\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CURLF":"Curaleaf Hldgs Inc."},"source_url":"https://www.thestreet.com/investing/curaleaf-buys-bloom-dispensaries-for-211-million?puc=yahoo&cm_ven=YAHOO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187597556","content_text":"The largest cannabis company in the country, Curaleaf(CURLF), plans to acquire Bloom Dispensaries in its efforts to grow its Arizona market.\nAs part of an all-cash deal valued at $211 million, the Wakefield, Mass.-based Curaleaf committed to purchasing the Arizona-based marijuana dispenser and two processing facilities Phoenix and multiple dispensaries in Tucson, Peoria, and Sedona.\nThe deal is expected to close in January 2022 after regulator approval.\nCuraleaf Has Big Expansion Plans\nThe move is part of Curaleaf's larger plan to expand its reach in different parts of the country and Arizona in particular — the Bloom acquisition will bring it up to 16 dispensaries in Arizona and 128 across the country.\nIt chose Bloom, which is expected to generate $66 million in revenue and EBITDA margins of more than 40%, for its \"attractive financial profile.\"\n\"Bloom has built a strong and profitable business, and we believe the combination of our two companies will enhance our competitive position and ability to continue gaining share in the highly attractive Arizona market,\" Curaleaf CEO Joseph Bayern said in a press statement.\nHow Is Curaleaf Paying for the Deal?\nCuraleaf will initially pay out $51 million in cash at closing. For the rest, it signed promissory notes of $50 million, $50 million, and $60 million due on the first, second, and third anniversary of the close.\nNews of the acquisition has not had an upward effect on the company's value. Curaleaf is 34.33% to $8.48 year-over-year and down 2.59% since this morning.\n\"In addition to bolstering our strong position in this key growth market with an attractive portfolio of retail and cultivation assets, Bloom will be immediately accretive to our adjusted EBITDA margins upon close,\" says Curaleaf Executive Chairman Boris Jordan.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2478,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696012684,"gmtCreate":1640573247955,"gmtModify":1640573248985,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"The sting from a thousand ants is no less painful, nor less deadlier, than a sting from a big bad bee.","listText":"The sting from a thousand ants is no less painful, nor less deadlier, than a sting from a big bad bee.","text":"The sting from a thousand ants is no less painful, nor less deadlier, than a sting from a big bad bee.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696012684","repostId":"2194177711","repostType":4,"isVote":1,"tweetType":1,"viewCount":1669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698470795,"gmtCreate":1640515785322,"gmtModify":1640515786372,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"Not all matches are made in heaven ","listText":"Not all matches are made in heaven ","text":"Not all matches are made in heaven","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698470795","repostId":"1144001147","repostType":4,"repost":{"id":"1144001147","kind":"news","pubTimestamp":1640485026,"share":"https://www.laohu8.com/m/news/1144001147?lang=&edition=full","pubTime":"2021-12-26 10:17","market":"us","language":"en","title":"A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State","url":"https://stock-news.laohu8.com/highlight/detail?id=1144001147","media":"InvestorPlace","summary":"In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, t","content":"<p>In the last year, <b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) stock is still among the top performers. During this period, the stock has surged by over 500%. The stock’s ascent began after Dec. 21, 2020 — starting from there, the stock is up over 1,600%.</p>\n<p>However, it’s worth noting that OCGN stock was trading well below one dollar before it stitched a partnership with <b>Bharat Biotech</b>. The companies announced plans to begin manufacturing Covid-19 vaccines in the U.S. on Dec. 22 last year.</p>\n<p>Beyond the news of this partnership, there has been little to cheer for investors. OCGN stock traded at all-time highs of $18.77 in February and reached slightly lower peaks in May and November. The stock traded at $5.12 at the start of Dec. 23.</p>\n<p>Ocugen will continue to underperform going forward. Even after the downtrend in the last few months, OCGN stock should be avoided.</p>\n<p>Let’s talk about the reasons to be bearish.</p>\n<p>FDA Approval Remains Elusive</p>\n<p><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>) and <b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>) have been leaders in the vaccine race in the U.S. In a country where more than 70% of the population has already been vaccinated, Ocugen has yet to secure an approval from the U.S. Food and Drug Administration.</p>\n<p>Back in June, the biotech company’s application for emergency use authorization was rejected by the FDA. The recommendation by the FDA was to file for a biologics license application, which implies full approval.</p>\n<p>In November, Ocugen announced that the FDA has “issued a clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate.” The FDA will be identifying the specific deficiencies that form a basis for the clinical hold. Once Ocugen addresses these deficiencies, there will be some progress.</p>\n<p>The key point is that it’s been over a year since Ocugen announced the partnership with Bharat Biotech. The company has still been unsuccessful from an approval perspective.</p>\n<p>In July, Ocugen had also initiated a rolling submission to Health Canada for the vaccine. There is no positive news on that front either.</p>\n<p>Let’s imagine a scenario where Ocugen receives an approval for vaccine use in Q1 2022. This is very unlikely. However, even in an optimistic case scenario, Ocugen needs to compete in a market where vaccination percentage is high. There is unlikely to be a case for strong revenue and cash flow growth.</p>\n<p>Can Omicron Provide a Lifeline for OCGN Stock?</p>\n<p>The omicron variant has been a cause of concern for governments globally. Ocugen and partner Bharat Biotech are currently studying the effectiveness of the vaccine against the variant.</p>\n<p>If the vaccine proves to be effective, can it be a game-changer for Ocugen? Most likely, no.</p>\n<p>First and foremost, Moderna has announced that its Covid-19 booster increases neutralizing antibodies 37-fold against Omicron variant.</p>\n<p>Furthermore, Pfizer has announced that a third dose increases the “neutralizing antibody by 25-fold compared to two doses against the Omicron variant.”</p>\n<p>Clearly, the leading vaccine makers have an edge. Even if Ocugen announces that its vaccine is effective against the omicron variant, the stock is unlikely to trend higher.</p>\n<p>People who have already taken two shots of Moderna or Pfizer are unlikely to pursue a booster shot with Ocugen. Additionally, Ocugen is still struggling for approval.</p>\n<p>It’s also worth noting that Ocugen needs to share revenue with Bharat Biotech. The visibility for healthy cash flows is therefore very unlikely.</p>\n<p>OCGN Stock Will Trend Lower</p>\n<p>OCGN stock is likely to continue trending lower in the coming months. Without an approval, the company is rapidly losing out on any revenue and cash flow potential.</p>\n<p>The company is building a pipeline of drugs for various indications. However, the pipeline for various indications is still at a pre-clinical stage.</p>\n<p>The stock trend will therefore be dictated by the outcome of Covid-19 vaccine approval and revenue potential. Things seem bleak on that front.</p>\n<p>It also seems unlikely that Ocugen has a capability to expand the vaccine partnership with Bharat Biotech to other countries.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Year After Announcing a Big Partnership, Ocugen Is in a Sorry State</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Year After Announcing a Big Partnership, Ocugen Is in a Sorry State\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:17 GMT+8 <a href=https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, the stock has surged by over 500%. The stock’s ascent began after Dec. 21, 2020 — starting from there...</p>\n\n<a href=\"https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://investorplace.com/2021/12/a-year-after-its-big-partnership-with-bharat-ocgn-stock-is-in-a-sorry-state/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144001147","content_text":"In the last year, Ocugen(NASDAQ:OCGN) stock is still among the top performers. During this period, the stock has surged by over 500%. The stock’s ascent began after Dec. 21, 2020 — starting from there, the stock is up over 1,600%.\nHowever, it’s worth noting that OCGN stock was trading well below one dollar before it stitched a partnership with Bharat Biotech. The companies announced plans to begin manufacturing Covid-19 vaccines in the U.S. on Dec. 22 last year.\nBeyond the news of this partnership, there has been little to cheer for investors. OCGN stock traded at all-time highs of $18.77 in February and reached slightly lower peaks in May and November. The stock traded at $5.12 at the start of Dec. 23.\nOcugen will continue to underperform going forward. Even after the downtrend in the last few months, OCGN stock should be avoided.\nLet’s talk about the reasons to be bearish.\nFDA Approval Remains Elusive\nPfizer(NYSE:PFE) and Moderna(NASDAQ:MRNA) have been leaders in the vaccine race in the U.S. In a country where more than 70% of the population has already been vaccinated, Ocugen has yet to secure an approval from the U.S. Food and Drug Administration.\nBack in June, the biotech company’s application for emergency use authorization was rejected by the FDA. The recommendation by the FDA was to file for a biologics license application, which implies full approval.\nIn November, Ocugen announced that the FDA has “issued a clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate.” The FDA will be identifying the specific deficiencies that form a basis for the clinical hold. Once Ocugen addresses these deficiencies, there will be some progress.\nThe key point is that it’s been over a year since Ocugen announced the partnership with Bharat Biotech. The company has still been unsuccessful from an approval perspective.\nIn July, Ocugen had also initiated a rolling submission to Health Canada for the vaccine. There is no positive news on that front either.\nLet’s imagine a scenario where Ocugen receives an approval for vaccine use in Q1 2022. This is very unlikely. However, even in an optimistic case scenario, Ocugen needs to compete in a market where vaccination percentage is high. There is unlikely to be a case for strong revenue and cash flow growth.\nCan Omicron Provide a Lifeline for OCGN Stock?\nThe omicron variant has been a cause of concern for governments globally. Ocugen and partner Bharat Biotech are currently studying the effectiveness of the vaccine against the variant.\nIf the vaccine proves to be effective, can it be a game-changer for Ocugen? Most likely, no.\nFirst and foremost, Moderna has announced that its Covid-19 booster increases neutralizing antibodies 37-fold against Omicron variant.\nFurthermore, Pfizer has announced that a third dose increases the “neutralizing antibody by 25-fold compared to two doses against the Omicron variant.”\nClearly, the leading vaccine makers have an edge. Even if Ocugen announces that its vaccine is effective against the omicron variant, the stock is unlikely to trend higher.\nPeople who have already taken two shots of Moderna or Pfizer are unlikely to pursue a booster shot with Ocugen. Additionally, Ocugen is still struggling for approval.\nIt’s also worth noting that Ocugen needs to share revenue with Bharat Biotech. The visibility for healthy cash flows is therefore very unlikely.\nOCGN Stock Will Trend Lower\nOCGN stock is likely to continue trending lower in the coming months. Without an approval, the company is rapidly losing out on any revenue and cash flow potential.\nThe company is building a pipeline of drugs for various indications. However, the pipeline for various indications is still at a pre-clinical stage.\nThe stock trend will therefore be dictated by the outcome of Covid-19 vaccine approval and revenue potential. Things seem bleak on that front.\nIt also seems unlikely that Ocugen has a capability to expand the vaccine partnership with Bharat Biotech to other countries.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1305,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698222515,"gmtCreate":1640414135741,"gmtModify":1640414136773,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"Why not just have them both","listText":"Why not just have them both","text":"Why not just have them both","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/698222515","repostId":"2193178191","repostType":4,"isVote":1,"tweetType":1,"viewCount":2026,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698226159,"gmtCreate":1640413684199,"gmtModify":1640413685236,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"Mostly highly unlikely, but highly unlikely tiny when they occur.","listText":"Mostly highly unlikely, but highly unlikely tiny when they occur.","text":"Mostly highly unlikely, but highly unlikely tiny when they occur.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698226159","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":2252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698223498,"gmtCreate":1640412940650,"gmtModify":1640412941679,"author":{"id":"3573703375513385","authorId":"3573703375513385","name":"JonLucky","avatar":"https://static.tigerbbs.com/15afb66e92e4e4d6d1a8e9b7854e9d5e","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573703375513385","authorIdStr":"3573703375513385"},"themes":[],"htmlText":"It's a matter of time ","listText":"It's a matter of time ","text":"It's a matter of time","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698223498","repostId":"693467733","repostType":1,"repost":{"id":693467733,"gmtCreate":1640065720060,"gmtModify":1640065720271,"author":{"id":"3582010039361860","authorId":"3582010039361860","name":"ngjr90","avatar":"https://static.tigerbbs.com/2904905ef5b1f52f808bd60775612fea","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582010039361860","authorIdStr":"3582010039361860"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>Will it breakeven?","listText":"<a href=\"https://laohu8.com/S/ES3.SI\">$STI ETF(ES3.SI)$</a>Will it breakeven?","text":"$STI ETF(ES3.SI)$Will it breakeven?","images":[{"img":"https://static.tigerbbs.com/84dd4f4e6d3b0c966cd4f91c586b353b","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693467733","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}